Some of the stocks that may grab investor focus today are:
Wall Street expects Deere & Company (NYSE: DE) to report its quarterly earnings at $0.75 per share on revenue of $6.13 billion. Deere shares surged 2.33 percent to close at $76.35 yesterday.
HP Inc (NYSE: HPQ) reported FQ4 non-GAAP earnings of $0.93 per share, versus the company's previously issued guidance of $0.92 to $0.98 per share. Its total revenue declined 9.5 percent to $25.71 billion. The company also issued a weak profit forecast on Tuesday. HP shares slipped 7.45 percent to $13.55 in the after-hours trading session.
Analysts are expecting Donaldson Company, Inc. (NYSE: DCI) to have earned $0.33 per share on revenue of $551.60 million in the latest quarter. Donaldson shares slipped 0.16 percent to close at $30.52 yesterday.
Guess?, Inc. (NYSE: GES) reported better-than-expected earnings for the third quarter on Tuesday. Guess? shares surged 4.45 percent to $20.41 in the after-hours trading session.
SolarCity Corp (NASDAQ: SCTY) appointed COO Tanguy Serra as its new President. The company also reported that its CFO Brad Buss will retire in 2016. SolarCity shares dipped 3.33 percent to $27.62 in the after-hours trading session.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ablynx (OTC: ABYLY) today announced that it has entered into a global exclusive collaboration and licensing agreement with Novo Nordisk (NYSE: NVO) to discover and develop novel multi-specific Nanobody® drug candidates for use in an undisclosed disease area, with an option to expand the agreement to include a second Nanobody programme.
Under the terms of the agreement, Ablynx will receive an upfront license fee of €5 million and up to €4 million in research funding during the initial three year research term of the collaboration. If Novo Nordisk decides to exercise the option to the second programme, the Company will pay Ablynx an exercise fee of €4 million. In addition, Ablynx is eligible to receive potential development, regulatory and commercial milestone payments of up to €182 million per programme plus tiered royalties on the annual net sales on any products resulting from the collaboration. Novo Nordisk will be responsible for the development, manufacturing and commercialisation of any products resulting from this agreement.
Dr Edwin Moses, CEO of
See full press release
Pandora (NYSE: P) announced Tuesday, the Register of Copyrights delivered
her Memorandum Opinion in response to a "novel material question of law"
referred to her on September 11, 2015 by the Copyright Royalty Board
(CRB). This was the second round of questioning referred to the Register
of Copyrights by the CRB in the "Webcasting IV" rate setting proceeding,
which will determine rates for the period of 2016-2020. A decision is
due in mid-December.
The question referred by the Judges asked whether they were prohibited
by the governing statutes from setting rates and terms that may differ
across different types of categories of licensors – in essence, whether
they can set statutory webcasting royalty rates that vary depending on
See full press release